AEON (AEON Biopharma) Risk Assessment

View and export this data going back to 2023. Start your Free Trial

What is AEON Biopharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of AEON Biopharma is: No Data: Cannot be evaluated.

Competitive Comparison of AEON Biopharma's Risk Assessment

For the Biotechnology subindustry, AEON Biopharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEON Biopharma's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEON Biopharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where AEON Biopharma's Risk Assessment falls into.

Save Embed

;

Save Embed

;

AEON Biopharma (AMEX:AEON) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

AEON Biopharma Risk Assessment Related Terms

Thank you for viewing the detailed overview of AEON Biopharma's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

AEON Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEON Biopharma Inc (AMEX:AEON) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Park Plaza, Suite 1750, Irvine, CA, USA, 92614

Website

https://www.aeonbiopharma.com

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Executives

Strathspey Crown Holdings Group, Llc	10 percent owner	4040 MACARTHUR BLVD., SUITE 210, NEWPORT BEACH CA 92660
Priveterra Sponsor, Llc	10 percent owner	300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Daewoong Co., Ltd	10 percent owner	244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO M5 13211
Alexander Blair Wilson	officer: Exec VP, CLO & Corp Secretary	5 PARK PLAZA, SUITE 1750, IRVINE CA 92614
Chad Oh	officer: Chief Medical Officer	C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Marc Forth	director, officer: Chief Executive Officer	C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPOER BEACH CA 92660
Jost Fischer	director	C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Oleg Grodnensky	10 percent owner	300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Vikram Malik	10 percent owner	17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Peter A Reynolds	officer: Chief Financial Officer	27442 PORTOLA PARKWAY, SUITE 200, FOOTHILL RANCH CA 92610
Robert J Palmisano	director, 10 percent owner	110 HARTWELL AVENUE, LEXINGTON MA 02173
Shelley B Thunen	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric G Carter	director	C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Meredith	officer: Chief Legal Officer&Secretary	300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301